Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Teva Jumps to Highest Since 2011 Amid Actavis Acquisition

Feb. 19 (Bloomberg) -- Teva Pharmaceutical Industries Ltd., the world’s largest maker of generic drugs, rallied in New York on prospects the company will benefit from the busiest year for health-care acquisitions since 2009.

Shares of Petach Tikva, Israel-based Teva added 2.3 percent to $46.74, the highest since July 2011. The shares increased 17 percent this year. The Bloomberg Israel-US Equity Index of the largest Israeli companies traded in New York retreated 0.6 percent.

Actavis Plc, the world’s second-largest generic-drug maker by market value, agreed yesterday to buy Forest Laboratories Inc. for about $25 billion. Pharmaceutical and biotechnology deals totaled about $110 billion in the 12 months through February, data compiled by Bloomberg show. That’s the most for any 12-month period since 2009, the data show.

“What we see is Teva’s reaction to the Actavis acquisition of Forest Laboratories,” Kevin Kedra, a health-care analyst at Gabelli & Co., who rates Teva a buy, said by phone from Rye, New York today. “There’s this general excitement; there is an expectation of further acquisitions.”

To contact the reporter on this story: Elena Popina in New York at

To contact the editor responsible for this story: Tal Barak Harif at

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.